573 related articles for article (PubMed ID: 29386395)
1. Anti-PD-1/anti-CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8
Taggart D; Andreou T; Scott KJ; Williams J; Rippaus N; Brownlie RJ; Ilett EJ; Salmond RJ; Melcher A; Lorger M
Proc Natl Acad Sci U S A; 2018 Feb; 115(7):E1540-E1549. PubMed ID: 29386395
[TBL] [Abstract][Full Text] [Related]
2. Control of established melanoma by CD27 stimulation is associated with enhanced effector function and persistence, and reduced PD-1 expression of tumor infiltrating CD8(+) T cells.
Roberts DJ; Franklin NA; Kingeter LM; Yagita H; Tutt AL; Glennie MJ; Bullock TN
J Immunother; 2010 Oct; 33(8):769-79. PubMed ID: 20842060
[TBL] [Abstract][Full Text] [Related]
3. Monotherapeutically nonactive CTLA-4 blockade results in greatly enhanced antitumor effects when combined with tumor-targeted superantigens in a B16 melanoma model.
Sundstedt A; Celander M; Eriksson H; Törngren M; Hedlund G
J Immunother; 2012 May; 35(4):344-53. PubMed ID: 22495392
[TBL] [Abstract][Full Text] [Related]
4. IL2/Anti-IL2 Complex Combined with CTLA-4, But Not PD-1, Blockade Rescues Antitumor NK Cell Function by Regulatory T-cell Modulation.
Caudana P; Núñez NG; De La Rochere P; Pinto A; Denizeau J; Alonso R; Niborski LL; Lantz O; Sedlik C; Piaggio E
Cancer Immunol Res; 2019 Mar; 7(3):443-457. PubMed ID: 30651291
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint Ab enhances the antigen-specific anti-tumor effects by modulating both dendritic cells and regulatory T lymphocytes.
Sun NY; Chen YL; Lin HW; Chiang YC; Chang CF; Tai YJ; Chen CA; Sun WZ; Chien CL; Cheng WF
Cancer Lett; 2019 Mar; 444():20-34. PubMed ID: 30543813
[TBL] [Abstract][Full Text] [Related]
6. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.
Duraiswamy J; Kaluza KM; Freeman GJ; Coukos G
Cancer Res; 2013 Jun; 73(12):3591-603. PubMed ID: 23633484
[TBL] [Abstract][Full Text] [Related]
7. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
[TBL] [Abstract][Full Text] [Related]
8. Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies.
Wei SC; Anang NAS; Sharma R; Andrews MC; Reuben A; Levine JH; Cogdill AP; Mancuso JJ; Wargo JA; Pe'er D; Allison JP
Proc Natl Acad Sci U S A; 2019 Nov; 116(45):22699-22709. PubMed ID: 31636208
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-33 pretreatment promotes metastatic growth of murine melanoma by reducing the cytotoxic capacity of CD8
Jevtovic A; Pantic J; Jovanovic I; Milovanovic M; Stanojevic I; Vojvodic D; Arsenijevic N; Lukic ML; Radosavljevic GD
Cancer Immunol Immunother; 2020 Aug; 69(8):1461-1475. PubMed ID: 32285171
[TBL] [Abstract][Full Text] [Related]
10. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
Allard B; Pommey S; Smyth MJ; Stagg J
Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic depletion of CCR8
Van Damme H; Dombrecht B; Kiss M; Roose H; Allen E; Van Overmeire E; Kancheva D; Martens L; Murgaski A; Bardet PMR; Blancke G; Jans M; Bolli E; Martins MS; Elkrim Y; Dooley J; Boon L; Schwarze JK; Tacke F; Movahedi K; Vandamme N; Neyns B; Ocak S; Scheyltjens I; Vereecke L; Nana FA; Merchiers P; Laoui D; Van Ginderachter JA
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589525
[TBL] [Abstract][Full Text] [Related]
12. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.
Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM
Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic T lymphocyte antigen-4 blockade enhances antitumor immunity by stimulating melanoma-specific T-cell motility.
Pentcheva-Hoang T; Simpson TR; Montalvo-Ortiz W; Allison JP
Cancer Immunol Res; 2014 Oct; 2(10):970-80. PubMed ID: 25038199
[TBL] [Abstract][Full Text] [Related]
14. Restoring anti-tumor functions of T cells via nanoparticle-mediated immune checkpoint modulation.
Li SY; Liu Y; Xu CF; Shen S; Sun R; Du XJ; Xia JX; Zhu YH; Wang J
J Control Release; 2016 Jun; 231():17-28. PubMed ID: 26829099
[TBL] [Abstract][Full Text] [Related]
15. Plexin-A4 Mediates Cytotoxic T-cell Trafficking and Exclusion in Cancer.
Celus W; Oliveira AI; Rivis S; Van Acker HH; Landeloos E; Serneels J; Cafarello ST; Van Herck Y; Mastrantonio R; Köhler A; Garg AD; Flamand V; Tamagnone L; Marine JC; Di Matteo M; Costa BM; Bechter O; Mazzone M
Cancer Immunol Res; 2022 Jan; 10(1):126-141. PubMed ID: 34815265
[TBL] [Abstract][Full Text] [Related]
16. Antibody-Mediated Phosphatidylserine Blockade Enhances the Antitumor Responses to CTLA-4 and PD-1 Antibodies in Melanoma.
Freimark BD; Gong J; Ye D; Gray MJ; Nguyen V; Yin S; Hatch MM; Hughes CC; Schroit AJ; Hutchins JT; Brekken RA; Huang X
Cancer Immunol Res; 2016 Jun; 4(6):531-40. PubMed ID: 27045021
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain.
Singh M; Vianden C; Cantwell MJ; Dai Z; Xiao Z; Sharma M; Khong H; Jaiswal AR; Faak F; Hailemichael Y; Janssen LME; Bharadwaj U; Curran MA; Diab A; Bassett RL; Tweardy DJ; Hwu P; Overwijk WW
Nat Commun; 2017 Nov; 8(1):1447. PubMed ID: 29129918
[TBL] [Abstract][Full Text] [Related]
18. Intratumoral follicular regulatory T cells curtail anti-PD-1 treatment efficacy.
Eschweiler S; Clarke J; Ramírez-Suástegui C; Panwar B; Madrigal A; Chee SJ; Karydis I; Woo E; Alzetani A; Elsheikh S; Hanley CJ; Thomas GJ; Friedmann PS; Sanchez-Elsner T; Ay F; Ottensmeier CH; Vijayanand P
Nat Immunol; 2021 Aug; 22(8):1052-1063. PubMed ID: 34168370
[TBL] [Abstract][Full Text] [Related]
19. Boiling histotripsy and in-situ CD40 stimulation improve the checkpoint blockade therapy of poorly immunogenic tumors.
Singh MP; Sethuraman SN; Miller C; Malayer J; Ranjan A
Theranostics; 2021; 11(2):540-554. PubMed ID: 33391491
[No Abstract] [Full Text] [Related]
20. Macrophages/Microglia Represent the Major Source of Indolamine 2,3-Dioxygenase Expression in Melanoma Metastases of the Brain.
Herrera-Rios D; Mughal SS; Teuber-Hanselmann S; Pierscianek D; Sucker A; Jansen P; Schimming T; Klode J; Reifenberger J; Felsberg J; Keyvani K; Brors B; Sure U; Reifenberger G; Schadendorf D; Helfrich I
Front Immunol; 2020; 11():120. PubMed ID: 32117271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
